dtpa-ferric-chelate and Breast-Neoplasms

dtpa-ferric-chelate has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for dtpa-ferric-chelate and Breast-Neoplasms

ArticleYear
Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Radiology, 2018, Volume: 286, Issue:2

    Purpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with those of a commercial gadolinium-based contrast agent for their applicability in dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging. Materials and Methods The animal experiments were approved by the local ethics committee. Two previously described iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) were synthesized with stability constants several orders of magnitude higher than those of gadolinium-based contrast agents. The T1 contrast effects of the two chelates were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7 T. For in vivo studies, a human breast cancer cell line (MDA-231) was implanted in five mice per group. The dynamic contrast effects of the chelates were compared by performing DCE MR imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same tumors with gadopentetate dimeglumine on day 2. Quantitative DCE maps were generated with software and were compared by means of a one-tailed Pearson correlation test. Results Relaxivities in serum (0.94 T at room temperature) of Fe-tCDTA (r1 = 2.2 mmol

    Topics: Animals; Breast Neoplasms; Contrast Media; Female; Ferric Compounds; Gadolinium; Gadolinium DTPA; Heterografts; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Phantoms, Imaging

2018